LIPG

1. LIPG lowers the risk of chronic kidney disease in humans (OR 0.89 [95% CI 0.82 to 0.96]).

   Humansfor each 1-SD decrease in HDL cholesterol in European ancestry

   The Role of Angiopoietin-Like Proteins 3 and 4 and Their Target Lipases in CKD: A Drug-Target Mendelian Randomization Study · American journal of kidney diseases : the official journal of the National Kidney Foundation · 22 Sep 2026

Chronic kidney disease →